Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 beginning at 1:30 p.m. Eastern Time.

A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, and Twitter/X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240506671205/en/

Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
[email protected]

Source: Quince Therapeutics, Inc.

You May Also Be Interested In

• Ermenegildo Zegna Group Reports First Half 2026 Revenues of €987 Million With Profit at €28 Million and Adjusted EBIT at €74 Million
• TXOne Networks Launches AI-Driven Edge Release, Bringing Zero-Disruption OT Protection to Virtual Infrastructure
• Xunce Technology Launches TokenCloud, Redefining the Value of Computing Power Through Full-Chain AI Infrastructure and Securing a Leading Position in the Token Economy Era